8-K: Cardinal Health Beats Q1 Expectations, Raises FY27 Outlook
Quarterly Results
Cardinal Health reported a strong first quarter for fiscal year 2027 with a 5% revenue increase to $67.5 billion and raised its full-year non-GAAP EPS guidance.
Summary
- Cardinal Health reported first quarter fiscal year 2027 revenues of $67.5 billion, a 5% increase year-over-year.
- GAAP operating earnings rose 13% to $753 million, and GAAP diluted EPS increased 27% to $2.38.
- Non-GAAP operating earnings grew 17% to $1.0 billion, with non-GAAP diluted EPS up 28% to $3.26.
- The company has raised its fiscal year 2027 non-GAAP EPS guidance to a range of $12.80 to $13.00.
- This updated guidance represents 17% to 19% growth from its FY26 ex-tariff refund baseline.
- Cardinal Health completed a $500 million share repurchase program in the first quarter.
Sentiment
Score: 8
Explanation: StockSavvy.ai views this as a positive report, with strong revenue growth, increased earnings, and an improved financial outlook, indicating solid operational performance and strategic execution.
Positives
- First quarter revenue increased by 5% to $67.5 billion.
- GAAP operating earnings saw a 13% increase, reaching $753 million.
- GAAP diluted EPS grew by a significant 27% to $2.38.
- Non-GAAP operating earnings increased by 17% to $1.0 billion.
- Non-GAAP diluted EPS showed a strong 28% increase, reaching $3.26.
- The company raised its fiscal year 2027 non-GAAP EPS outlook to $12.80-$13.00.
- Pharmaceutical and Specialty Solutions segment profit increased by 17% to $783 million.
- Completed a $500 million share repurchase program.
Negatives
- Global Medical Products and Distribution segment profit decreased by 28% to $33 million, primarily due to unfavorable distribution and foreign exchange impacts.
- Global Medical Products and Distribution segment revenue was flat year-over-year.
Risks
- Risks associated with managing uncertainties in branded pharmaceutical pricing, including proposed or final regulatory changes.
- Potential failure to achieve strategic objectives, including successful operation of acquired entities and execution of improvement plans.
- Risks and uncertainties related to tariffs, including the inability to offset increased costs.
- Risks arising from geopolitical conflicts, such as the conflict with Iran, potentially leading to cost increases or supply disruptions.
- Litigation risks, including Department of Justice investigations into potential violations of the Anti-Kickback Statute and False Claims Act.
- Risks related to the performance of the generics program, including the rate of generic deflation and the ability to offset it.
Future Outlook
Cardinal Health has raised its fiscal year 2027 non-GAAP diluted EPS guidance to a range of $12.80 to $13.00, representing 17% to 19% growth from its FY26 ex-tariff refund baseline and 14% to 15% growth from reported FY26 results. The company also raised its outlook for Pharmaceutical and Specialty Solutions profit growth to 10% to 12% and Other profit growth to 17% to 20%. The non-GAAP effective tax rate is expected to be between 18.5% and 19.5%, and diluted weighted average shares outstanding are projected to be 231 million to 232 million.
Management Comments
- "Our results reflect a strong start to fiscal 2027 and demonstrate consistent execution against our strategic priorities," said Jason Hollar, CEO of Cardinal Health.
- "We continue to benefit from focused investments, disciplined operations and the strength of our diversified portfolio."
- "Given this quarter's strong performance and our updated expectations for the remainder of the year, we are raising our fiscal 2027 non-GAAP EPS outlook."
Industry Context
StockSavvy.ai notes that Cardinal Health's performance in the pharmaceutical and medical distribution sector appears robust, with significant revenue and earnings growth. The raised outlook suggests the company is navigating industry dynamics effectively, potentially outperforming competitors who may be facing greater margin pressures or slower growth in certain segments.
Comparison to Industry Standards
- The 5% revenue growth for the quarter is a solid performance in the healthcare distribution sector, which often experiences moderate growth rates.
- The significant increase in non-GAAP diluted EPS (28%) suggests strong operational leverage and effective cost management, which is a positive indicator compared to industry peers who might be experiencing margin compression.
- The raised full-year EPS guidance indicates confidence in sustained performance, which is a key differentiator in an industry where predictability is highly valued by investors.
Legal Proceedings
- Department of Justice investigations focused on potential violations of the Anti-Kickback Statute and False Claims Act.
Stakeholder Impact
- Shareholders: Positive impact due to increased earnings, raised guidance, and completion of a $500 million share repurchase program.
- Suppliers: Continued strategic relationship with CVS Health through renewed pharmaceutical distribution agreements.
- Employees: Potential impact from restructuring and employee severance costs, though these are excluded from non-GAAP measures.
Next Steps
- Continue execution against strategic priorities.
- Benefit from focused investments and disciplined operations.
- Anticipate completing the acquisition of AdaptHealth's Diabetes Health business in Q3 of fiscal 2027.
- Launch real-world evidence study INSIGHT-IBD in partnership with Eli Lilly.
- Utilize additional $1.0 billion in uncommitted revolving credit facilities.
Key Dates
| Date | Description |
|---|---|
| September 30, 2026 | End of the first quarter of fiscal year 2027. |
| November 5, 2026 | Date of the report and announcement of first quarter fiscal year 2027 results. |
| June 30, 2027 | End of fiscal year 2027. |
| Q3 of fiscal 2027 | Anticipated completion of the acquisition of AdaptHealth's Diabetes Health business. |
Recommendation
holdThe company delivered strong Q1 results and raised its FY27 outlook, demonstrating solid execution and positive momentum. However, the decrease in profit for the Global Medical Products and Distribution segment warrants caution. While the overall outlook is positive, a 'hold' recommendation allows for further observation of segment performance and broader market conditions before considering a more aggressive stance.
Keywords
Cardinal Health, Q1 Earnings, Fiscal Year 2027, Revenue Growth, EPS Guidance, Share Repurchase, Pharmaceutical Distribution, Medical Products
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.